Tom Tang: Assessing DVT Risk Before It Happens
Tom Tang, Sale Director at Xiamen Senyang Co.,Ltd., shared a post on LinkedIn:
“Assessing a patient’s risk for deep vein thrombosis (DVT) is the first step in formulating a prevention plan.
In clinical practice, this relies on standardized, quantified Risk Assessment Models (RAMs) for precise stratification, combined with a comprehensive evaluation of the patient’s clinical presentation and laboratory/imaging indicators.
1. Core DVT Risk Assessment Models (RAMs)
For different departments and patient populations, clinical practice primarily utilizes the following three mainstream stratification tools:
a. Caprini Risk Assessment Model (primarily for: surgical/operative patients)
The Caprini model is currently the most widely used scoring system in the surgical field.
It accumulates scores based on the weighted risk factors (1, 2, 3, or 5 points):
- Low Risk (0–1 points): e.g., Patients undergoing minor procedures without other risk factors. Recommendation: Early ambulation.
- Moderate Risk (2 points): e.g., Patients aged 41–60, undergoing minor surgery, or non-surgical patients requiring bed rest. Recommendation: Graduated compression stockings (GCS) or mechanical prophylaxis (e.g., Intermittent Pneumatic Compression [IPC]).
- High Risk (3–4 points): e.g., Age more than 60, laparoscopic surgery more than 45 minutes, active malignancy, or a history of DVT. Recommendation: Pharmacological prophylaxis combined with mechanical prophylaxis (IPC).
- Very High Risk (greater than or equal to 5 points): e.g., Total hip/knee arthroplasty, acute spinal cord injury, or multiple trauma. Recommendation: Mandatory combined pharmacological prophylaxis (e.g., Low Molecular Weight Heparin [LMWH]) and mechanical prophylaxis (IPC).
b. Padua Prediction Score (Primarily for: Medically Ill Hospitalized Patients)
For non-surgical medical patients (a cumulative score of grater than or equal to 4 defines high risk):
- High-Risk Factors (3 points each): Active malignancy, previous VTE, restricted mobility (bed rest grater than or equal to 3 days), known thrombophilia.
- Moderate-Risk Factors (2 points each): Recent (less than or equal to 1 month) trauma or surgery.
- Low-Risk Factors (1 point each): Advanced age (grater than or equal to 70 years), heart or respiratory failure, acute myocardial infarction or acute ischemic stroke, acute infection or rheumatologic disease, obesity (BMI grater than or equal to 30), hormone therapy.
2.Post-stratification intervention strategies (stratified prophylaxis)
Based on the assessed risk levels, international guidelines (such as ACCP) recommend a stepwise approach to prophylaxis:
Risk Level – Recommended Prophylaxis Measures
- Low Risk – Encourage early ambulation and adequatehydration.
- Moderate Risk – Physical/Mechanical Prophylaxis: Use Intermittent Pneumatic Compression (IPC) devices or Graduated Compression Stockings (GCS).
- High / Very High Risk – Combined Prophylaxis: Anticoagulant medication (e.g., LMWH) and IPC mechanical compression. (IPC significantly accelerates lower limb blood flow velocity while mitigating bleeding risks).”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 18, 2026, 05:48Julie Taylor: Navigating Tech Glitches to Deliver Engaging BBTS Presentation
-
Sep 18, 2026, 05:42Emma Copperwaite: BBTS Conference Presentation Highlights Power of Peer Support and Pushing Past Fear
-
Sep 18, 2026, 05:34Suhasini Sil: RGSSH Joins Mega Blood Donation Camp at Thyagaraj Stadium
-
Sep 18, 2026, 05:25Lisa Laun: Spleen Clears Activated Platelets to Limit Thrombosis and Inflammation
-
Sep 18, 2026, 05:16Louise St. Germain Bannon: ISTH Advocates for Enhanced Patient Safety in Blood Disorder Care
-
Sep 18, 2026, 05:08Vikas Veer: Exploring Sickle Cell Anemia at the Molecular Level
-
Sep 18, 2026, 01:35Matthew Hazell: From Platelet Refractoriness to Protecting Transplanted Organs
-
Sep 18, 2026, 01:23Apple Joy A. Valenzuela: Exploring How Neutrophil Develops from the Myeloblast to the Mature Segmented Neutrophil
-
Sep 18, 2026, 01:13Su Someh: Gaps and Variation in Global Plasma Donor Protection Policies